Patent · US Active

Dosing regimen for a selective S1P1 receptor agonist

US10857134B2 · kind B2 · utility

0Cited by

16References

8Claims

0Family size

Assignee

Actelion Pharmaceuticals Ltd. · CH

Inventors

Jasper Dingemanse · Allschwil, CH
Matthias Hoch · Harston, GB
Andreas Krause · Frankfurt am Main, DE

Key dates

Filing date	Jan 29, 2019
Grant date	Dec 8, 2020
Priority date	—
Expiry date	Jan 29, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.